Share This Article:

Use of Rituximab in Refractory Dermatomyositis: A Case Report

DOI: 10.4236/ojra.2013.31006    3,995 Downloads   6,403 Views  
Author(s)    Leave a comment


We report a case of a 56-year-old female with a confirmed diagnosis of Dermatomyositis on muscle biopsy, which was refractory to 5 different disease modifying drugs as well as intravenous immunoglobulins and symptoms improved dramatically with a single course of Rituximab. We hereby wish to highlight the importance of Rituximab in this highly resistant case and that anti CD 20 biologic drugs can be considered as standard treatment protocol in refractory Dermatomyositis.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

K. Grover and R. Peshin, "Use of Rituximab in Refractory Dermatomyositis: A Case Report," Open Journal of Rheumatology and Autoimmune Diseases, Vol. 3 No. 1, 2013, pp. 31-32. doi: 10.4236/ojra.2013.31006.


[1] P. H. Plotz, M. Dalakas, R. L. Leff, L. A. Love, F. W. Miller and M. E. Cronin, “Current Concepts in the Idiopathic Inflammatory Myopathies: Polymyositis, Dermatomyositis, and Related Disorders,” Annals of Internal Medicine, Vol. 111, No. 2, 1989, pp. 143-157.
[2] T. P. O’Hanlon, D. M. Carrick, I. N. Targoff, F. C. Arnett, J. D. Reveille, M. Carrington, X. Gao, C. V. Oddis, P. A. Morel, J. D. Malley, K. Malley, E. A. Shamim, L. G. Rider, S. J. Chanock, C. B. Foster, T. Bunch, P. J. Blackshear, P. H. Plotz, L. A. Love and F. W. Miller, “Immunogenetic Risk and Protective Factors for the Idiopathic Inflammatory Myopathies,” Medicine (Baltimore), Vol. 85, No. 2, 2006, pp. 111-127. doi:10.1097/
[3] M. C. Dalakas and R. Hohlfeld, “Polymyositis and Dermatomyositis,” The Lancet, Vol. 362, No. 9388, 2003, pp. 971-982. doi:10.1016/S0140-6736(03)14368-1
[4] M. L. Miller and S. A. Rudnicki, “Treatment of Recurrent and Resistant Dermatomyositis and Polymyositis in Adults.”
[5] E. H. Noss, D. L. Hausner-Sypek and M. E. Weinblatt, “Rituximab as Therapy for Refractory Polymyositis and Dermatomyositis,” The Journal of Rheumatology, Vol. 33, No. 5, 2006, pp. 1021-1026.
[6] E. A. Mahler, M. Blom, N. C. Voermans, B. G. van Engelen, P. L. van Riel and M. C. Vonk, “Rituximab Treatment in Patients with Refractory Inflammatory Myopathies,” Rheumatology (Oxford), Vol. 50, No. 12, 2011, pp. 2206-2213. doi:10.1093/rheumatology/ker088
[7] T. D. Levine, “Rituximab in the Treatment of Dermatomyositis: An Open-Label Pilot Study,” Arthritis & Rheumatism, Vol. 52, No. 2, 2005, pp. 601-607. doi:10.1002/art.20849
[8] A. E. Hak, B. de Paepe, J. L. de Bleecker, P. P. Tak and M. de Visser, “Dermatomyositis and Polymyositis: New Treatment Targets on the Horizon,” Netherlands Journal of Medicine, Vol. 69, No. 10, 2011, pp. 410-421.
[9] V. Limaye, P. Hissaria, C. L. Liew and B. Koszyka, “Efficacy of Rituximab in Refractory Antisynthetase Syndrome,” Internal Medicine Journal, Vol. 42, No. 3, 2012, pp. e4-e7.
[10] I. Marie and L. Mouthon, “Therapy of Polymyositis and Dermatomyositis,” Autoimmunity Reviews, Vol. 11, No. 1, 2011, pp. 6-13. doi:10.1016/j.autrev.2011.06.007

comments powered by Disqus

Copyright © 2019 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.